PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

PHASE3CompletedINTERVENTIONAL
Enrollment

535

Participants

Timeline

Start Date

October 4, 2006

Primary Completion Date

December 11, 2009

Study Completion Date

December 11, 2009

Conditions
Clostridium InfectionsDiarrhea
Interventions
DRUG

PAR-101/OPT-80

capsules

DRUG

Vancomycin

Capsules

Trial Locations (116)

Unknown

Gadsden

Phoenix

Hot Springs

La Mesa

Modesto

Palm Springs

Rancho Mirage

San Jose

Santa Ana

Vallejo

Washington D.C.

Miami

Port Orange

Sarasota

Marietta

Savannah

Idaho Falls

Chicago

Maywood

Indianapolis

Bowling Green

Jena

New Orleans

Baltimore

Boston

West Roxbury

Detroit

Keego Harbor

Royal Oak

Minneapolis

Tupelo

Columbia

Butte

Cedar Knolls

Neptune City

The Bronx

Charlotte

Winston-Salem

Fargo

Akron

Amherst

Cleveland

Columbus

Dayton

Philadelphia

Pittsburgh

Charleston

Rapid City

Sioux Falls

San Antonio

Winchester

Seattle

Charleston

Aalst

Alast

Antwerp

Brussels

Columbia

Ghent

Kortrijk

Liège

Mons

Montigny-le-Tilleul

Wilrijk

Calgary

Edmonton

Hamilton

Toronto

Chicoutimi

Montreal

Saint-Jérôme

Sherbrooke

Trois-Rivières

Amiens

Caen

Clichy

Garches

Grenoble

Lille

Tourcoing

Tours

Valenciennes

Cologne

Düsseldorf

Frankfurt

Hanover

Hofheim am Taunus

Lübeck

Magdeburg

Regensburg

Busto Arsizio

Genova

Milan

Modena

Torino

Badalona

Barcelona

Madrid

Palma de Mallorca

Seville

Eskilstuna

Gothenburg

Örebro

Great Yarmouth

Derriford

Barnsley

Brighton

Cambridge

Edinburgh

Liege

London

Nottingham

Oxford

Oxon

Surrey

York

All Listed Sponsors
lead

Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00468728 - PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) | Biotech Hunter | Biotech Hunter